Due to the COVID-19 pandemic, the ACP office is now closed as our staff work remotely. Click here to see how this impacts our programs and operations.

Reminder: prescription codeine-containing oral liquids changed to Type 1

July 8, 2020

Affected products now require a secure, two-part TPP Alberta prescription form.

Pharmacy teams are reminded that as of July 1, 2020, oral liquids containing codeine requiring a prescription are now classified as Type 1 within Alberta’s triplicate prescription program (TPP). As a result, these products require the secure TPP Alberta, two-part prescription form.

The dispenser must be presented with the top copy of the TPP secure form. The prescriber should retain the second copy. The form may also be faxed from the prescriber. For compounds, office use, and veterinarians and Yukon prescriptions, a photocopy must be made by the dispenser and submitted to TPP for monitoring and the original form or fax must be retained by the pharmacy.

Drug products currently affected include

  • Acetaminophen Elixir with 8 mg Codeine Phosphate syrup,
  • pms-Acetaminophen with Codeine Elixir,
  • Calmylin ACE,
  • Coactifed,
  • Dimetane C Expectorant,
  • Dimetapp C,
  • Robitussin AC,
  • Teva-Cotridin Expectorant,
  • Teva-Cotridin,
  • Codeine Phosphate Syrup (Laboratoire Atlas Inc.), and
  • Linctus Codeine Blanc (Laboratoire Atlas Inc.).
For more on the TPP Alberta program, visit the CPSA website.

← Previous ArticleNext Article →